These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 20547785

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
    Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A.
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4771-8. PubMed ID: 22733064
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
    Juan C, Zamorano L, Pérez JL, Ge Y, Oliver A, Spanish Group for the Study of Pseudomonas, Spanish Network for Research in Infectious Diseases.
    Antimicrob Agents Chemother; 2010 Feb; 54(2):846-51. PubMed ID: 19933793
    [Abstract] [Full Text] [Related]

  • 6. Antibiotic-induced lipopolysaccharide (LPS) release from Salmonella typhi: delay between killing by ceftazidime and imipenem and release of LPS.
    van Langevelde P, Kwappenberg KM, Groeneveld PH, Mattie H, van Dissel JT.
    Antimicrob Agents Chemother; 1998 Apr; 42(4):739-43. PubMed ID: 9559775
    [Abstract] [Full Text] [Related]

  • 7. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.
    Zamorano L, Juan C, Fernández-Olmos A, Ge Y, Cantón R, Oliver A.
    Clin Microbiol Infect; 2010 Sep; 16(9):1482-7. PubMed ID: 20002107
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Target affinities of faropenem to and its impact on the morphology of gram-positive and gram-negative bacteria.
    Dalhoff A, Nasu T, Okamoto K.
    Chemotherapy; 2003 Jul; 49(4):172-83. PubMed ID: 12886052
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antibacterial properties of SCE-2787, a new cephem antibiotic.
    Nakao M, Noji Y, Iwahi T, Yamazaki T.
    J Antimicrob Chemother; 1992 May; 29(5):509-18. PubMed ID: 1624391
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC, Fiorenza MA, Estrada SJ.
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [Abstract] [Full Text] [Related]

  • 19. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, Tsuji M, Yamano Y.
    J Antimicrob Chemother; 2018 Nov 01; 73(11):3049-3052. PubMed ID: 30188999
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.